Navigation Links
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
Date:2/22/2010

Biotech leaders enable Talaris’ capacity to deliver unprecedented, cross-functional expertise for all phases of drug development.

(PRWEB) February 22, 2010 -- In a move that forms one of biotech's most experienced strategic drug development groups, a team of veteran industry executives has joined Talaris Advisors, strengthening the company's capacity to provide expertise for all phases of drug development. Talaris works with biotech managers, companies and investors to optimize their use of capital and maximize exit outcomes for drug development programs.

Led by Mark J. Pykett, Chief Executive Officer, the Talaris management team has added the following industry veterans: Noel Cusack, PhD, Senior Vice President Nonclinical Development; Susan Flint, Senior Vice President Drug Development; Mark R. Hurtt, MD, Chief Medical Officer; Richard Thorn, PhD, Senior Vice President CMC; and James Weston, Senior Vice President Regulatory Affairs and Quality.

"Real strategic drug development expertise is determined by a team's insight and ability to accelerate milestones when taking a project through a wide range of regulatory scenarios and by creating a range of exit options based on the commercial and medical value of the assets. Our clients and investors are excited by Talaris’ expansion because it confirms our ability to provide this level of expertise and deftly address the complexities of drug development particularly in the current environment,” comments Mark J. Pykett, Talaris CEO. "Each new manager is a distinguished leader who has an average of 30 years of experience, in addition to having important networks and relationships to provide the best performance outcomes for drug compounds and investors."

By any measure, the drug development industry is challenged by the escalating cost and time it takes to develop drugs combined with increasingly complex and challenging regulatory, reimbursement and financing environments. Biotech leaders are working hard to find ways to improve both efficiency and effectiveness in drug development without losing key drivers for innovation. Biotech companies and investors engage Talaris to avoid the typical ramp-up, wind-down or carrying costs associated with drug development management while delivering integrated risk and cost optimized development programs.

The Talaris management team is composed of recognized leaders whose expertise spans the continuum of all key development disciplines: non-clinical, regulatory, medical, clinical operations, manufacturing and quality.

The industry veterans enhance Talaris’ capacity to manage projects strategically and successfully, having managed hundreds of development programs, clinical trials and regulatory submissions. In their careers with companies such as Pfizer, DuPont, Baxter and others, the team has taken over 30 products through to the market.

About Talaris Advisors
Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at www.talarisadvisors.com.

###

Read the full story at http://www.prweb.com/releases/Talaris_Advisors/drug_development/prweb3626744.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members
2. FDA Advisors Declare FDA Science and Mission at Risk
3. Perceptive Informatics Appoints Medical Imaging Scientific Advisors
4. NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo
5. FDA Advisors Declare FDA Science and Mission at Risk
6. Brian Bastis Elected as National CPA Health Care Advisors Association Executive Committee President
7. Cosmetic Bootcamp Announces Record Attendance and Sponsorship and Names Members of Its Board of Advisors
8. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
9. As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors
10. SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray
11. Emageon Selects Jefferies & Company and SunTrust Robinson Humphrey as Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers 
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... Westchester County, NY (PRWEB) , ... March 24, 2017 , ... ... in Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. ... as a law clerk for the firm, will concentrate her practice in elder law, ...
(Date:3/24/2017)... ... 24, 2017 , ... Empower Brokerage, located in Southlake, Texas, ... programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program ... to teach how to maximize their sales efforts, as well as how to ...
(Date:3/24/2017)... ... ... Time GPS”: a dauntless and enlightened study of the second-coming of Christ, and ... published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation as ... ninety-one, he shares the Wisdom God bestowed upon him in this publication. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “The Adventures of ... smart and silly dog who lives his life to the fullest, as God intended. ... published author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)...  GenomeDx Biosciences today announced that six abstracts featuring ... Cancer Classifier tests will be presented at the 32 ... held March 24 to 28, 2017 in ... Europe,s largest urological event showcasing ... field. The abstract titled "Muscle invasive bladder ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: